Technology · Health & biomedicine / Regenerative & personalized medicine

Non-CAR cell immunotherapy (iPSC-derived NK cells and others)

Living immune cells — TILs, CIK cells, dendritic cells, off-the-shelf iPSC-derived NK cells — used against cancer; an iPSC-derived NK product has entered Phase I in China.

Maturity 4/9 Risk: high Advanced therapies CN verified 2026-10-16 · 4 Sources

1 · What it gives

Non-CAR immune cell therapy uses living immune cells such as tumour-infiltrating lymphocytes, cytokine-induced killer cells or dendritic cells. Advanced allogeneic products are meant to replace or augment conventional autologous therapies, which are patient-specific, costly, slow to make and hard to standardise. Evidence of progress: Nuwacell’s iPSC-derived NK product NCR300 entered Phase I clinical trials in China.

2 · What it replaces 6

D2	Industrial biocatalysis (enzymes and whole cells) — e.g. nitrile hydratase for acrylamide, engineered transaminase for sitagliptin, enzymatic antibiotic side-chain processes — instead of heavy-metal catalysts, high-pressure hydrogenation and multistep chemistry with toxic reagents Replaces: Copper-catalysed sulfuric-acid hydration of acrylonitrile; rhodium-catalysed high-pressure asymmetric hydrogenation; chemical deacylation of …	CHEM
D1	Plant-based meat and dairy analogues and cultivated (cell-cultured) meat and seafood instead of a share of conventional meat and its antibiotic, antiparasitic and feed-chain chemical inputs Replaces: A share of conventional meat, seafood and dairy — and the antibiotics, antiparasitics, feed-crop pesticides and fertilizer of the animal …	NOVEL
D2	Disease-resistant crop varieties (marker-assisted breeding, stacked resistance genes, cisgenesis) instead of routine fungicide spray programmes Replaces: Season-long protective fungicide programmes on susceptible varieties — e.g. 10–20 sprays of mancozeb/chlorothalonil/metalaxyl against potato …	SEED
D1	Disease-resistant livestock genetics — genomic selection, adapted breeds, gene-edited PRRS-resistant pigs — instead of routine antibiotics, acaricides and repeated mass treatment Replaces: Metaphylactic antibiotics used against secondary infections after PRRS and other viral diseases; frequent acaricide dipping of …	BREED
D1	Fish louse (Argulus) control in ponds and lakes with egg-laying substrate boards, pond drying/liming and biological management — instead of organophosphate treatments Replaces: Organophosphates in pond water (trichlorfon/metrifonate, dichlorvos), pyrethroids (deltamethrin) and emamectin used against Argulus and …	SERV
D1	Garden, allotment and lawn pest control with beneficial nematodes — Phasmarhabditis against slugs, Steinernema/Heterorhabditis against vine weevil, chafer grubs, leatherjackets — instead of metaldehyde pellets and soil insecticides Replaces: Metaldehyde slug pellets (banned outdoors in Great Britain from 2022), methiocarb pellets (EU non-renewed), soil insecticides in gardens and …	MACRO

3 · How to implement 3 steps

1
Select the source
Select a source such as stem cells or donor cells.
2
Engineer
Apply genetic engineering, for example with CRISPR.
3
Manufacture and test
Manufacture the cell product, then test it clinically.

4 · Who delivers

Matched suppliers (matched automatically)

Avani	Indonesia	Producer	active
Lootah BioFuels	United Arab Emirates	Producer	active
Accra Compost and Recycling Plant Limited	Ghana	Producer	active
BioTerra	Uruguay	Services / consulting	active
Aristogene Biosciences Pvt. Ltd.	India	Producer	active
CH4 Global	United States	Research / RTO	active
Esco Aster	Singapore	Services / consulting	active
GenScript ProBio / Genscript	China	Research / RTO	active
Georem International	South Africa	Services / consulting	active
Incauca	Colombia	Producer	active
Jiangsu Boyang Bioproducts	China	Research / RTO	active
Liselo Labs	South Africa	Research / RTO	active

Leading companies and institutes (from the brief)

Nuwacell Biotechnologies is named as developing off-the-shelf iPSC-derived NK cell products for cancer. Others are matched by the portal under Advanced therapies.

5 · Rules & route to market

Route into Russia / EAEU: CHEM · Minpromtorg (registration) / Rospotrebnadzor (notification of new substances)
state registration ~10-15 working days after expert assessment; new substances need notification
Information, not legal advice — confirm the procedure for your product. (2026-10-06)

United States

The sources reviewed on 2026-10-16 identified no the US regulator or standard specific to this technology. Treat the route as case-by-case and ask for a check.

European Union

The sources reviewed on 2026-10-16 identified no the EU regulator or standard specific to this technology. Treat the route as case-by-case and ask for a check.

China

In China the NMPA and its Center for Drug Evaluation (CDE) regulate cell therapy products as innovative biological products and issue technical guidance.

6 · Money: tenders & grants

Grant	Advancing bio-printing of living cells for regenerative medicine European Commission · EU	Sep 22, 2027 341 days
Grant	Capacity building for extending product lifecycles through repair and refurbishment European Commission · EU	Sep 22, 2027 341 days
Grant	Deploying circular systemic solutions through living labs in cities and regions (Circular Cities and Regions … European Commission · EU	Apr 8, 2027 174 days
Grant	Living Labs for the eradication and/or management of invasive alien species European Commission · EU	Sep 22, 2027 341 days
Grant	Living labs driving transformative change via knowledge integration and inclusive governance European Commission · EU	Sep 22, 2027 341 days

7 · Tech stack & innovations

Main risks from the sources: cytokine release syndrome, graft-versus-host disease, graft rejection, and challenges in product standardisation and manufacturing.

Sources 4

Pmc.ncbi.nlm.nih.gov — pmc.ncbi.nlm.nih.gov 2026-10-16
Mdpi.com — www.mdpi.com 2026-10-16
M.nuwacell.com — m.nuwacell.com 2026-10-16
Pmc.ncbi.nlm.nih.gov — pmc.ncbi.nlm.nih.gov 2026-10-16